AHK-Cu (Copper Tripeptide)

What it is

Copper peptides are short amino acid chains that hold on to a copper ion and bring it to where cells need it. The best known is GHK-Cu, whose regenerative effect Loren Pickart described in 1973. AHK-Cu differs from it by a single amino acid: instead of glycine, alanine sits in first position, while histidine and lysine remain. The histidine is the anchor for the copper.

This small change has major consequences for the evidence, because research followed the original and not the variant. For GHK-Cu there are decades of papers, for AHK-Cu one. According to suppliers, AHK-Cu is offered as a cosmetic raw material for serums and scalp care, and also as a research peptide for self-experimentation.

Why copper is the starting point

The reason copper peptides sound plausible at all lies not in the peptide but in the metal. Copper is a cofactor of lysyl oxidase, which cross-links collagen and elastin and thus determines the firmness and elasticity of skin and connective tissue. It is also found in superoxide dismutases, that is, in the cell’s own defense against oxygen radicals, in cytochrome c oxidase of the respiratory chain and in the transport protein ceruloplasmin. A deficiency accordingly shows up in connective tissue, blood formation and nerves.

For the peptide class, it has been described that tripeptide-copper complexes stimulate skin fibroblasts to divide, increase the production of the vascular growth factor VEGF and reduce the release of TGF-beta1. This is of interest for the hair root, because its supply depends on small blood vessels. The step from this class description to AHK-Cu itself, however, is exactly the step the data take only once.

The paper on which everything rests

A Korean group tested AHK-Cu in 2007 in two models. The first consists of isolated human hair follicles that continue to grow in nutrient solution, the second of cultured dermal papilla cells, the specialized connective tissue cells at the base of the follicle that control the hair cycle. AHK-Cu was active in both, and at concentrations of 10 to the power of -12 to 10 to the power of -9 moles per liter: the follicles grew in length, and the cells divided more often.

The paper answers the question of why only halfway. Stains for cell death showed fewer dying dermal papilla cells, but the difference was not statistically significant. The protein findings were clearer: the ratio of the protective Bcl-2 to its counterpart Bax increased, and the cleaved, that is, active forms of caspase-3 and PARP decreased. The authors accordingly phrase it cautiously: AHK-Cu promotes the growth of human follicles, and this could be related to the division and protection of dermal papilla cells. An animal experiment, an application on the head and a comparison with minoxidil are missing.

What else exists

Beyond this paper, things get thin. A search of the literature database Europe PMC for AHK-Cu returns 5 hits, and only the one mentioned studied AHK-Cu itself; the rest are reviews and passing mentions. One of these reviews, from 2026, classifies AHK-Cu as experimental evidence from organ culture and explicitly states that its signaling pathway is less well characterized than that of GHK-Cu. The closest is a 2018 paper on a derivative: AHK linked to a vitamin C building block enhanced BMP-2-induced differentiation into bone cells in a mouse cell line via Smad1/5/8, ERK1/2 and p38, without notable cytotoxicity. That is a different substance in a different tissue and says nothing about hair.

A look at the sister peptide

Anyone who wants to put AHK-Cu into perspective should know how far the better-studied variant has come, because that is the realistic benchmark. For GHK there is a study in 45 men with hereditary hair loss: 6 months of applying a complex of 5-aminolevulinic acid and the peptide in two strengths versus placebo. Hair count rose by 52.6 and 71.5 versus 9.6 under placebo, no side effects occurred, and hair length and hair thickness did not differ. That is a genuine human finding, but with a combination product, a small group and a mixed picture of endpoints — and it concerns GHK, not AHK. In other words: even the top of this peptide class rests on narrow data, and AHK-Cu stands one level below.

What the studies show

Pyo et al. 2007: the original paper

Two models, both with human material: isolated hair follicles in organ culture and cultured dermal papilla cells. AHK-Cu lengthened the follicles and increased cell division at 10 to the power of -12 to 10 to the power of -9 moles per liter. The decrease in dying cells was not statistically significant; the ratio of Bcl-2 to Bax increased, and cleaved caspase-3 and cleaved PARP decreased. Endpoints were follicle length and cell count, not hair growth on a human being.

Jung et al. 2018: the derivative

What was studied was not AHK-Cu but AHK with a vitamin C building block, developed for collagen synthesis and fibroblast growth. In a mouse myoblast cell line, the substance enhanced BMP-2-induced differentiation into bone cells, measurable by alkaline phosphatase, and activated Smad1/5/8 as well as ERK1/2 and p38. Pure cell culture, no animal, no human.

Lee et al. 2016: the benchmark for the sister peptide

45 men with hereditary hair loss received a complex of 5-aminolevulinic acid and GHK in two strengths or placebo for 6 months. Hair count rose by 52.6 and 71.5 versus 9.6 under placebo; the comparison of change ratios was statistically significant for one active group versus placebo, hair length and hair thickness did not differ, and no side effects occurred. What was tested was GHK, not AHK-Cu.

Where the data stop

The limit is easy to name: there is no application in humans. No randomized trial, no study on the scalp or skin, no entry in ClinicalTrials.gov, no pharmacokinetics, no measurement of how much of a copper peptide gets through the skin at all. This also leaves open whether the concentrations from organ culture are ever reached in a serum on the scalp.

Two further limitations belong here. The proposed mechanism via less cell death was not statistically significant in the original paper; what is established is follicle lengthening and cell division, not their explanation. And the figures are already being passed on inaccurately: the 2026 review gives a range of 10 to the power of -13 to 10 to the power of -7 moles per liter for the same paper, while the abstract of the original paper states 10 to the power of -12 to 10 to the power of -9. For injected use, which occurs on the gray market, there is no study at all.

Status, approval and legal

AHK-Cu is not an approved medicine in Germany, the EU or the US, and no clinical trial is registered. According to suppliers, it is sold as a cosmetic raw material; for this route, the EU Cosmetics Regulation requires a safety assessment of the finished product and a responsible person, but no individual approval of a peptide and no proof of efficacy. As a food supplement, AHK-Cu may not be marketed: the relevant EU directive lists 8 permitted copper compounds, and copper tripeptides are not among them. AHK-Cu is also traded as a research peptide, which is not a regulatory framework. Because it is not an approved active substance, no amounts or concentrations for use are given here; the values from cell culture are study facts. In sport, copper peptides are not named on the 2026 WADA Prohibited List; for injectable products without approval, the section on non-approved substances applies in principle.

Safety

For AHK-Cu itself there is no safety study in humans; in cell culture it was not cytotoxic at the concentrations tested. The rest follows from the copper. The recommended intake for adults in the US is 900 micrograms per day, the tolerable upper intake level 10 milligrams per day; persistently too much copper damages the liver and causes gastrointestinal complaints. In 2023 the EFSA concluded that no accumulation in the body is to be expected at 5 milligrams per day and derived an acceptable daily intake of 0.07 milligrams per kilogram of body weight. AHK-Cu is not for people with a disorder of copper metabolism, such as Wilson’s disease, or for people with a copper allergy. Anyone considering injected gray-market products should know what a 2026 review summarizes for unregulated injectable peptides: impurities, manufacturing residues and incorrect content labeling, without a reliable safety profile.

Sources

• Pyo et al., Arch Pharm Res 2007 – AHK-Cu and human hair follicles in organ culture
• Fan et al., Biomedicines 2026 – review of short peptides in hair loss
• Jung et al., Differentiation 2018 – vitamin C-conjugated AHK in mouse myoblasts
• Lee et al., Ann Dermatol 2016 – complex of 5-aminolevulinic acid and GHK in 45 men
• NIH Office of Dietary Supplements – Copper Fact Sheet
• EFSA Scientific Committee, EFSA J 2023 – copper, accumulation and acceptable daily intake
• Moiz et al., Mo Med 2026 – risks of unregulated injectable peptides
• Directive 2002/46/EC, Annex II – permitted copper compounds
• ClinicalTrials.gov – no registered trial on AHK-Cu